Takeda has doubled down on KSQ Therapeutics, handing over “double-digit millions of dollars” on day one and committing up to $510 million on the back end to research and validate novel tumor-intrinsic ...
LEXINGTON, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, including engineered ...
KSQ-004EX is a CRISPR/Cas9 engineered eTIL therapy targeting SOCS1 and Regnase-1 genes in solid tumors. The phase 1/2 trial evaluates safety, tolerability, and antitumor activity in advanced solid ...
PARP inhibitors like Lynparza from Merck and AstraZeneca have been effective in some patients with ovarian and breast cancers, but many develop resistance to the drugs, and some people don’t respond ...
LEXINGTON, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed ...
– Proprietary CRISPRomics™ Drug Discovery Engine Pinpoints the Best Therapeutic Nodes of Diseases; Product Insights Being Translated into Drug Candidates – CAMBRIDGE, Mass.--(BUSINESS WIRE)--KSQ ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--KSQ Therapeutics today announced the appointment of Douglas Pagán as Chief Financial Officer. Mr. Pagán brings more than 25 years of financial and operational ...
- KSQ Therapeutics to receive non-exclusive access to certain CRISPR IP for its autologous cell therapies, including its existing eTIL™ cell franchise - “We are thrilled to gain access to CRISPR ...
Advances in genome editing have dramatically transformed the scientific landscape and opened up significant new avenues for drug discovery and disease treatment. The editing tools known as CRISPR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results